US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Global Blood Therapeutics, Inc. - Common Stock (NQ:GBT)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 4, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Global Blood Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Biotech Stocks Well-Positioned For The Fourth Quarter ↗
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
News headline image
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022 ↗
We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022. 
Via Talk Markets
News headline image
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
News headline image
Global Blood Therapeutics's Return On Capital Employed Overview ↗
Benzinga Pro data, Global Blood Therapeutics (NASDAQ:GBT) reported Q2 sales of $71.55 million. Earnings fell to a loss of $82.47 million, resulting in a 1.29% decrease from last quarter. 
Via Benzinga
News headline image
Where Global Blood Therapeutics Stands With Analysts ↗
  Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings: 
Via Benzinga
News headline image
Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics ↗
The deal adds to Pfizer's efforts to tackle sickle cell disease. 
Via Investor's Business Daily
News headline image
Pfizer Scoops Up Sickle Disease Player For $5B ↗
 
Via Benzinga
News headline image
Global Blood Therapeutics's Return On Capital Employed Overview ↗
Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $71.55 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 1.29%, resulting in a loss of $82.47... 
Via Benzinga
News headline image
After Pfizer, Now Novo Nordisk Beefs Up Its Sickle Cell Portfolio With Forma Therapeutics Deal ↗
 
Via Benzinga
News headline image
GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
News headline image
Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million ↗
The biopharma buying spree continued Tuesday with glaucoma drugs maker Aerie. 
Via Investor's Business Daily
News headline image
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review ↗
The major indexes continued to advance, despite some key warnings. 
Via Investor's Business Daily
News headline image
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US ↗
 
Via Benzinga
News headline image
8 Analysts Have This to Say About Global Blood Therapeutics ↗
  Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022 ↗
  
Via Benzinga
News headline image
Global Blood Therapeutics: Q2 Earnings Insights ↗
  Global Blood Therapeutics (NASDAQ:GBT) reported its Q2 earnings results on Monday, August 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal ↗
Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT). 
Via Benzinga
News headline image
TBLT, RDBX: The Top 5 Short Squeeze Stocks to Watch This Week ↗
Short squeeze stocks are still a hot topic this week and we're listing five of the shares investors will want to keep an eye on! 
Via InvestorPlace
News headline image
GBT Stock Alert: Pfizer Is Officially Acquiring Global Blood Therapeutics ↗
GBT stock is already rallying on takeover talk. Now that Pfizer has confirmed the buyout, Global Blood Therapeutics is red hot. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022 ↗
  
Via Benzinga
News headline image
Global Blood (GBT) Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Global Blood Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – GBT
From Halper Sadeh LLP
Via Business Wire
News headline image
Benzinga Before The Bell: Elon Musk Confirms Tesla AI Day Part 2, Dogecoin Scam, BioNTech Q2 Earnings Shocker And Other Top Financial Stories Monday, August 8 ↗
CNBC Celsius Withdraws Motion To Rehire CFO 
Via Benzinga
News headline image
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday ↗
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
News headline image
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday ↗
Gainers 
Via Benzinga
News headline image
Small Cap Biotechs Perk Up On Dealmaking ↗
With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology. 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
  
Via Benzinga
News headline image
A Preview Of Global Blood Therapeutics's Earnings ↗
Global Blood Therapeutics (NASDAQ:GBT) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion ↗
Shares of Pfizer's rumored takeover target have rocketed for two days running. 
Via Investor's Business Daily
< Previous 1 2 3 4 Next >